Oxycodone and Nalbuphine Interaction

Drug interaction information between Oxycodone and Nalbuphine.

Oxycodone and Nalbuphine have a documented moderate interaction in FDA labeling.

FDA drug labeling documents a moderate-severity interaction between Oxycodone and Nalbuphine. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Oxycodone

Opioid Analgesic

Drug B

Nalbuphine

Opioid Agonist-Antagonist

How They Interact

Combining these medications can lead to a dangerous increase in breathing problems and muscle weakness.

FDA Label Information

Intervention: Avoid concomitant use Examples: Butorphanol, nalbuphine, pentazocine, buprenorphine Muscle Relaxants Clinical Impact: Oxycodone may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.

Oxycodone Also Interacts With

View all Oxycodone interactions →

Frequently Asked Questions

What SPL severity band is on file for Oxycodone + Nalbuphine?

Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Oxycodone has 28 labeled pairs on file vs Nalbuphine's 19. In the moderate band specifically: Oxycodone has 6 (also Carbamazepine, Rifampin, Buprenorphine, Butorphanol); Nalbuphine has 1.

What mechanism field is on file for Oxycodone and Nalbuphine?

Combining these medications can lead to a dangerous increase in breathing problems and muscle weakness.

Oxycodone's labeled portfolio outnumbers Nalbuphine

SPL source-record counts only. This page's band is moderate · classes on file: Oxycodone (Opioid Analgesic); Nalbuphine (Opioid Agonist-Antagonist).

Oxycodone

0 major · 6 moderate · 22 minor · 28 total

Nalbuphine

0 major · 1 moderate · 18 minor · 19 total

Nalbuphine has no other moderate-band peer in this dataset besides Oxycodone.

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.